For people who have lost their central vision to an incurable eye disease, a small implant and a pair of special glasses are offering something that once seemed impossible: the ability to see shapes and letters again.
Science Corporation, a neurotechnology company based in Alameda, California, announced a $400 million Series D funding round on Tuesday, November 17, according to Tech Startups. Investors include Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator and PLC Neurotech. No lead investor was named.
TechCrunch, citing a person familiar with the deal, reported that the round values the company at $3.5 billion. The company did not disclose a valuation. Science, founded in 2021, says it has raised more than $900 million since its founding.
How PRIMA works
Science's main product is PRIMA, a system designed to help some people with late-stage retinal disease perceive visual forms, according to Tech Startups. It combines a tiny wireless photovoltaic chip implanted under the retina with a pair of glasses fitted with a camera.
The camera captures images and projects them onto the implant using near-infrared light. The implant converts the light into electrical signals that stimulate the remaining retinal cells, which pass the signals to the brain. Patients learn to interpret these signals as visual forms.
PRIMA is aimed at patients with geographic atrophy, an advanced form of age-related macular degeneration that destroys the light-sensing cells in the central retina, causing loss of central vision. The condition affects millions of older people worldwide, and there has been no way to restore lost vision.
Clinical evidence
Results from a clinical trial of PRIMA, published in the New England Journal of Medicine in 2025, showed that many patients with geographic atrophy were able to read letters and words after receiving the implant and undergoing training, a significant improvement over their previous vision.
PRIMA has a European CE mark and is commercially available in parts of Europe, according to Tech Startups. In the United States, Science is seeking authorisation from the Food and Drug Administration through the Humanitarian Device Exemption pathway and does not claim existing FDA clearance.
Beyond the eye
Science is also developing biohybrid neural interfaces, which combine engineered neurons with electronics, according to Tech Startups. The approach differs from conventional brain-computer interfaces, which use electrodes implanted in the brain to record or stimulate neural activity.
The idea is to grow living neurons on a device that can then integrate with the brain, potentially creating more natural and scalable connections between the brain and computers. This research is at an early stage but could eventually be used to treat neurological conditions or restore lost functions.
The founder
Science was founded by Max Hodak, a co-founder and former president of Neuralink, Elon Musk's brain-computer interface company. Hodak left Neuralink in 2021 to start Science, which has taken a different approach by focusing first on vision restoration, an area with clear medical need and a path to commercialisation.
Investors' interest in neurotechnology
The $400 million round reflects growing investor interest in neurotechnology. Neuralink has raised large sums and begun human trials of its brain implant, while companies such as Synchron, Precision Neuroscience and Paradromics are developing devices to help people with paralysis communicate and control computers.




